Haematologic malignancies associated with clozapine v. all other antipsychotic agents: a pharmacovigilance study in VigiBase®
Authors:
- 10 February 2020
- journal article
- research article
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 51 (9) , 1459-1466
Abstract
Background: Clozapine is mainly used in patients with treatment-resistant schizophrenia and may lead to potentially severe haematologic adverse events, such as agranulocytosis. Whether clozapine might be associated with haematologic malignancies is unknown. We aimed to assess the association between haematologic malignancies and clozapine using Vigibase®, the WHO pharmacovigilance database.Methods: We performed a disproportionality analysis to compute reporting odds-ratio adjusted for age, sex and concurrent reporting of antineoplastic/immunomodulating agents (aROR) for clozapine and structurally related drugs (loxapine, olanzapine and quetiapine) compared with other antipsychotic drugs. Cases were malignant lymphoma and leukaemia reports. Non-cases were all other reports including at least one antipsychotic report.Results: Of the 140 226 clozapine-associated reports, 493 were malignant lymphoma cases, and 275 were leukaemia cases. Clozapine was significantly associated with malignant lymphoma (aROR 9.14, 95% CI 7.75–10.77) and leukaemia (aROR 3.54, 95% CI 2.97–4.22). Patients suffering from those haematologic malignancies were significantly younger in the clozapine treatment group than patients treated with other medicines (p < 0.001). The median time to onset (available for 212 cases) was 5.1 years (IQR 2.2–9.9) for malignant lymphoma and 2.5 years (IQR 0.6–7.4) for leukaemia. The aROR by quartile of dose of clozapine in patients with haematologic malignancies suggested a dose-dependent association.Conclusions: Clozapine was significantly associated with a pharmacovigilance signal of haematologic malignancies. The risk-benefit balance of clozapine should be carefully assessed in patients with risk factors of haematologic malignancies. Clozapine should be used at the lowest effective posology.Keywords
This publication has 36 references indexed in Scilit:
- Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance databaseBritish Journal of Clinical Pharmacology, 2011
- Memory disorders associated with consumption of drugs: updating through a case/noncase study in the French PharmacoVigilance DatabaseBritish Journal of Clinical Pharmacology, 2011
- Detection and quantitation of N-(deoxyguanosin-8-yl)-2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine adducts in DNA using online column-switching liquid chromatography tandem mass spectrometryJournal of Chromatography B, 2010
- Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia RegistryBlood, 2009
- The application of knowledge discovery in databases to post‐marketing drug safety: example of the WHO databaseFundamental & Clinical Pharmacology, 2008
- Epidemiology of Schizophrenia: Review of Findings and MythsPsychiatric Clinics of North America, 2007
- Clozapine, agranulocytosis, and benign ethnic neutropeniaPostgraduate Medical Journal, 2005
- Prescribing of clozapine and olanzapine: dosage, polypharmacy and patient ethnicityPsychiatric Bulletin, 2004
- Use of Measures of Disproportionality in PharmacovigilanceDrug Safety, 2002
- Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reportsPharmacoepidemiology and Drug Safety, 2001